Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.68
- Piotroski Score 4.00
- Grade Overweight
- Symbol (XAIR)
- Company Beyond Air, Inc.
- Price $0.54
- Changes Percentage (3.81%)
- Change $0.02
- Day Low $0.52
- Day High $0.56
- Year High $2.36
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.00
- High Stock Price Target $1.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.13
- Trailing P/E Ratio -0.55
- Forward P/E Ratio -0.55
- P/E Growth -0.55
- Net Income $-60,242,000
